Raphael Eric Steiner, MD
Department of Lymphoma and Myeloma, Division of Cancer Medicine
About Dr. Raphael Eric Steiner
Dr. Raphael Steiner, is an Assistant Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center. After a successful medical training in Switzerland in Internal Medicine/Family Practice and Medical Oncology, he completed a Lymphoma/Myeloma fellowship at MD Anderson Cancer Center. Dr. Steiner is currently Master Clinician in Lymphoma.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
My clinical research focuses on creating innovative frontline treatments for high grade B-cell lymphoma and Hodgkin Lymphoma. Through optimal combination of immunotherapies and/or chemotherapies, I investigate new regimens to reduce the risk of relapse and decrease toxicities.
Clinical Interests
My clinical interests include high grade lymphomas (diffuse large B-cell lymphoma, Primary mediastinal B-cell lymphoma and Burkitt lymphoma) and Hodgkin lymphoma (classical Hodgkin Lymphoma and Nodular lymphocyte-predominant Hodgkin's lymphoma)
Education & Training
Degree-Granting Education
| 2006 | Lausanne University, Lausanne, CHE, MD, Master of Medicine |
| 2003 | Lausanne University, Lausanne, CHE, BS, Bachelor of Medicine |
Postgraduate Training
| 2016-2017 | Clinical Fellowship, Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX |
| 2014-2016 | Clinical Fellowship, Medical Oncology, Zurich University Hospital, Zurich |
| 2007-2013 | Clinical Residency, Internal Medicine/Family Practice, Zurich University Hospital, Zurich |
Board Certifications
| 2017 | Swiss Medical Association (FMH) in Medical Oncology |
| 2014 | Swiss Medical Association (FMH) in General Interal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Faculty Academic Review Committee, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2021
Other Appointments/Responsibilities
General Hematology and Oncology Attending, State Hospital Aarau, Aarau, 2017 - 2018
Honors & Awards
| 2006 | Swiss Federal Examination in Medicine final boards, Lausanne University |
| 2003 | Erasmus-Socrates European Union Grant |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. PMID: 31036721.
- Steiner R, Kridel R, Giostra E, McKee T, Achermann R, Mueller N, Manuel O, Dickenmann M, Schuurmans MM, de Leval L, Fehr T, Tinguely M, Binet I, Cogliatti S, Haralamvieva E, Koller M, The Swiss Transplant Cohort Study Stcs , Dietrich PY. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. Swiss Med Wkly 148:w14596, 2018. e-Pub 2018. PMID: 29518251.
- Steiner RE, Romaguera J, Wang M. Current trials for frontline therapy of mantle cell lymphoma. J Hematol Oncol 11(1):13, 2018. e-Pub 2018. PMID: 29374487.
- Steiner RE, Orlowski RZ, Lee HC. Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient. Acta Haematol 139(1):67-70, 2018. e-Pub 2018. PMID: 29402766.
- Steiner RE, Manasanch EE. Carfilzomib boosted combination therapy for relapsed multiple myeloma. Onco Targets Ther 10:895-907, 2017. e-Pub 2017. PMID: 28243125.
- Steiner R, Beyer J. [Post treatment follow-up of patients with testicular cancer by primary care physicians]. Praxis (Bern 1994) 103(3):125-32; quiz 131, 2014. PMID: 24468451.
- Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma:1-7. e-Pub 2018. PMID: 30227761.
Abstracts
- Jason Westin, Loretta J. Nastoupil, Luis Fayad, Fredrick B. Hagemeister, Yasuhiro Oki, Francesco Turturro, Sairah Ahmed, Maria Alma Rodriguez, Hun Ju Lee, Raphael Steiner, Ranjit Nair, Simrit Parmar, Ken H Young, Timothy McDonnell, Hubert Chuang, Michael Richard Green, Sattva Swarup Neelapu, Richard Eric Davis. Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. ASCO Abstract, 2019.
- Kartik Anand, Ethan Burns, Dahlia Sano, Sai Ravi Pingali, Jason Westin, Loretta J. Nastoupil, Hun Ju Lee, Felipe Samaniego, Simrit Parmar, Michael Wang, Misha Hawkins, Sherry Adkins, Luis Fayad, Raphael Steiner, Ranjit Nair, Sairah Ahmed, Nathan Hale Fowler, Sattva Swarup Neelapu, Swaminathan Padmanabhan Iyer;. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. ASCO Abstract(Abstract No: 2540), 2019.
- J.R. Westin, L. Nastoupil, F. Hagemeister, L. Fayad, K. Young, T. McDonnell, H. Chuang, S. Ahmed, R. Nair, R. Steiner, H. Lee, M. Rodriguez, S. Parmar, M. Green, S. Neelapu, R. Davis. SMART START: RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE PRIOR TO COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA. Hematological ONCOLOGY ICML Abstract(Abstract No: 042), 2019.
- J.R. Westin, L. Nastoupil, L. Fayad, F. Hagemeister, K. Young, T. McDonnell, S. Neelapu, R.E. Davis, M. Green, S. Ahmed, R. Nair, R. Steiner, H. Lee, M. Rodriguez, S. Parmar, H. Chuang. VERY EARLY FDG PET/CT SCAN MAY PREDICT OUTCOMES IN RELAPSED OR REFRACTORY DLBCL PATIENTS TREATED WITH SALVAGE THERAPY. Hematological ONCOLOGY ICML Abstract(Abstract No: 367), 2019.
- B. Dabaja, M. Gule-Monroe, J.R. Gunther, S. Milgrom, T. Sheu, R. Nair, S. Ahmed, R. Steiner, P. Strati, L. Nastoupil, S. Neelapu, C. Pinnix, N. Fowler. DIFFUSE LARGE B CELL LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT: CAN MRI PATTERN HELP PREDICTING OUTCOME?. Hematological ONCOLOGY ICML Abstract(Abstract No: 406), 2019.
- P. Strati, P. Alcedo Andreade, D. Sano, V. Rao, P. Singh, R. Miranda, J. Gunther, C. Pinnix, B. Dabaja, H.J. Lee, R. Steiner. RELAPSED AND REFRACTORY NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL): A US ANALYSIS FROM MD ANDERSON CANCER CENTER. Hematological ONCOLOGY ICML Abstract(Abstract No: 471), 2019.
- Dahlia Sano, Loretta J. Nastoupil, Nathan H. Fowler, Luis Fayad, F. B. Hagemeister, Hun Ju Lee, Felipe Samaniego, Michael Wang, Maria Alma Rodriguez, Swaminathan P Iyer, Simrit Parmar, Raphael Steiner, Ranjit Nair, Sherry Adkins, Sara Arafat, Ahalya Rao, Liliana Vallejo, Misha Hawkins, Yiming Chen, Jason R. Westin, and Sattva S. Neelapu. Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell LymphomaClinically Relevant Abstract. ASH Annual Meeting 2018, 2018.
- Chaudhry M, Steiner RE, Claussen CM, Patel K, Lee HC, Weber DM, Thomas SK, Feng C, Kramer M, Amini B, Orlowski RZ, Feng L, Manasanch EE. Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for Multiple Myeloma and Waldenström's Macroglobulinemia. ASH Abstract 130(Suppl 1):1880. e-Pub 2017.
- Steiner RE, Fanale MA. New Strategies for the Treatment of Early Stage Classical Hodgkin Lymphoma (cHL). Clinical Lymphoma, Myeloma & Leukemia 17:S153–S155. e-Pub 2017.
Book Chapters
- Karp DD, Falchook G. Lymphoma. In: Handbook of Targeted Cancer Therapy and Immunotherapy. second. Wolters Kluwer, 2018.
Grant & Contract Support
| Title: | |
| Funding Source: | Swiss Transplant Cohort Study |
| Role: | Principal Investigator |